Weizmann immunotherapy shows early safety in Alzheimer's trial

In a small clinical trial across eleven medical centers in Britain, Israel, and the Netherlands, researchers tested a new approach to Alzheimer's disease that turns conventional thinking on its head. Rather than attacking the amyloid plaques that accumulate in aging brains, the experimental drug IBC-Ab002 works by reawakening the immune system's ability to protect the brain itself. The trial enrolled forty patients with early-stage Alzheimer's and found the therapy safe and well tolerated at every dose tested, with measurable changes in biological markers associated with nerve damage and the loss of connections between brain cells. The results, published in Nature Medicine, represent preliminary but meaningful evidence for an immune-focused strategy that has been years in the making.

The science behind this approach emerged from the laboratory of Michal Schwartz, a neuroscientist at Israel's Weizmann Institute of Science and a laureate of the Israel Prize in life sciences. For decades, Schwartz has challenged a foundational assumption in neurology: that immune activity in the brain is inherently destructive and should be suppressed. Her research suggests the opposite—that as we age, our immune system weakens, and this decline allows chronic inflammation to take root in the brain, accelerating the progression of Alzheimer's and other neurodegenerative diseases. About ten years ago, her team demonstrated in mouse models that temporarily loosening immune suppression through a specific molecular pathway could clear away aging cells, reduce inflammation, and improve memory. The pathway they targeted, called PD-1/PD-L1, had already proven useful in cancer treatment. ImmunoBrain, a company co-founded by Schwartz, licensed this technology and engineered IBC-Ab002 as a humanized antibody designed specifically for Alzheimer's disease, though it works on the same immune checkpoint that some cancer drugs exploit.

The clinical trial itself was deliberately modest in scope, as Phase 1 trials typically are. The primary goal was not to prove the drug slows cognitive decline—that would require much larger studies over longer periods—but simply to establish that it could be given safely to human patients. The forty participants were spread across five centers in the United Kingdom, five in Israel, and one in the Netherlands. Researchers, led by Schwartz and including Dr. Tommaso Croese, a former doctoral student in her lab now serving as vice president of clinical development at ImmunoBrain, found no safety concerns. The drug was well tolerated, and the biological markers they measured—indicators of neuronal damage and synaptic dysfunction—showed improvement consistent with the therapy's intended mechanism.

What makes this result noteworthy is not that it proves the drug works, but that it opens a door to a fundamentally different way of thinking about Alzheimer's treatment. The field has recently embraced drugs that directly target amyloid plaques, the sticky protein clumps that are a hallmark of the disease. Those drugs have shown modest benefits in slowing cognitive decline in early stages. But they do not address what Schwartz and her colleagues believe is a root cause: the aging of the immune system itself and the chronic brain inflammation that follows. "Aging is the greatest risk factor for Alzheimer's disease," Schwartz said in a statement accompanying the results. "One of the key contributors to disease progression is the aging of the immune system. Age-related decline in immune function fuels chronic inflammation in the brain, a major driver of the progression of Alzheimer's disease and other neurodegenerative disorders."

The next step is clear but demanding. The trial was small, and the results are preliminary. Larger studies will be needed to determine whether IBC-Ab002 can meaningfully slow the cognitive decline that defines Alzheimer's, whether it can alter the underlying disease process, and whether patients actually feel better and live better lives. Schwartz has articulated an ambitious goal: to restore the immune system's youthful capacity to protect the brain, potentially arresting the disease or even reversing it. That remains speculative. But the safety data from this Phase 1b trial suggests the approach is worth pursuing further, and as populations age and dementia prevalence rises globally, the search for new mechanisms of action has never been more urgent.